drugset / Trial / NCT04108897

Analysis of the Microbiome in Rosacea

NCT04108897

Phase 0 Active not recruiting 150 enrolled Johns Hopkins University
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The skin and gut microbiome of rosacea patients differs from individuals without rosacea and that the microbiome suffers from unique derangements in rosacea patients following antibiotic therapy. This study was proposed to examine microbial signatures of the skin and gut microbiome in patients with moderate to severe rosacea and to identify differences between microbe communities in patients with rosacea and volunteers without rosacea using 16S ribosomal ribonucleic acid (rRNA) polymerase chain reaction (PCR) amplification, sequencing and computational phylogenetics and to assess alterations in the gut and skin microbiota of patients with moderate to severe rosacea in response to varying formulations of antimicrobial treatment.

Timeline

Start
2019-09-17
Primary completion
2027-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 40 mg Oral
Subject Doxycycline Small molecule 50 mg Oral
Subject Doxycycline Small molecule 100 mg Oral
Subject Ivermectin Small molecule 1 % Topical

Indications